Academic Program

Program

Thursday, October 27, 2022

[8:00-9:15] Session I 

WM Predisposition

Mary McMaster, Alessandra Trojani [Chairs]

 

GWAS Study Findings in Familial Plasma Cell Dyscrasias incl. WM

Mary McMaster, National Institutes of Health, USA

 

Clonal Lymphopoiesis and predisposition to WM

Bruno Paiva, University of Navarra, Spain

 

Common gene set signature in IGM MGUS and WM by transcriptome analysis

Alessandra Trojani, Ospedale Metropolitano Niguarda, Italy

 

Twin Genomic Studies in WM: Identification of FHL2 Gene Mutation

Jian Hou, Renji Hospital, Shanghai Jiao Tong University, China

 

Clonal Hematopoiesis and risk of WM Progression

Adam Sperling, Dana Farber Cancer Institute, USA

 

[9:15-10:45] Session II

WM Genomics I

Bruno Paiva, Zachary Hunter [Chairs]

 

Comprehensive WES Study of WM-300 project

Zachary Hunter, Dana Farber Cancer Institute, USA

 

Genomic differences of CXCR4 wild-type and mutated clones

Cristina Jimenez, University of Salamanca, Spain

 

Integration of cytogenetic and molecular screening for first line patients

Damien Roos-Weil, Hôpital Pitié-Salpêtrière, France

 

 

Genomic Variants in Chinese Patients with WM

Shuhua Yi, Tianjin Medical Center, China

 

Lon Non-Coding RNA Expression in IGM MGUS and WM

Jonas Paludo, Mayo Clinic, USA

 

Single Cell Analysis of MYD88 mutated and wild-type WM

Tina Bagratuni, University of Athens, Greece

 

[10:45-11:15] Morning Break

 

[11:15-12:45] Session III

WM Genomics II

Marzia Varettoni, Nikhil Munshi [Chairs]

 

DNA Methylation Profiling in WM

Damien Roos-Weil, Hôpital Pitié-Salpêtrière, France

 

Epigenomic Regulation by ATAC Seq

Zachary Hunter, Dana Farber Cancer Institute, USA

 

Genomic studies in WM: first results from the BIOWM study of Fondazione Italiana Linfomi (FIL)

Marzia Varettoni, University of Pavia, Italy

 

Distinct Genomic Profile Characterizes IGM MM from WM

Nikhil Munshi, Dana Farber Cancer Institute, USA

 

Genomic Landscape of WM reveals late developing CAN

Kylee MacLachlan, Memorial Sloan Kettering Cancer Center, USA

 

Proteomic and Metabolomic Studies in WM

Shahrzad Jalali, Mayo Clinic, USA

 

[12:45-13:45] LUNCH

 

[13:45-14:15] Keynote Lectures

 

What the genomics of WM tells us about its curability

Keynote Speaker: Steven Treon, Dana Farber Cancer Institute, USA

 

Targeting the Epigenome: Opportunities for WM

Keynote Speaker: Ari Melnick, Cornell University, USA

 

 

 

[14:15-15:45] Session IV

Transgenic Models for WM

Ruben Carrasco, Jose Martinez-Climent, [Chairs]

 

MYD88 Transgenic Model

Klaus Rajewsky, Max Delbrück Center for Molecular Medicine, Germany

 

MYD88 L265P Transgenic Model

Ruben Carrasco, Dana Farber Cancer Institute, USA

 

Unraveling and targeting the immune microenvironment in MYD88 lymphomas

Jose Martinez-Climent, University of Navarra, Spain

 

Continuous activation of mutated MYD88

Christelle Vincent-Fabert, UMR CNRS/INSERM, France

 

CXCR4 Transgenic Model

Karl Balabanian, Inserm Unité Mixte de Recherche S996, France

 

TBL1XR1 Transgenic Model

Ari Melnick, Cornell University, USA

 

[15:45-16:15] Afternoon Break

 

[16:15-17:30] Session V

Signalomics in WM

Irene Ghobrial, Aldo Roccaro [Chairs]

 

MYD88 driven HCK pro-survival signaling

Guang Yang, Dana Farber Cancer Institute, USA

 

Mutated MYD88 related Ubiquitination

Yong Li, Baylor College of Medicine, USA

 

ERK dysregulation mediated by aberrant WNK2 expression

Maria Luisa Guerrera, Dana Farber Cancer Institute, USA

 

FGF/FGF-R Axis in MYD88 Mutated WM

Aldo Roccaro, ASST Spedali Civili di Brescia, Italy

 

Genomic evolution of ibrutinib resistant clones

Cristina Jimenez, University of Salamanca, Spain

 

[17:30] Day Adjournment

 

[18:00] Poster Presentations & Dinner Reception

Presentation of Young Investigator Awards

Presentation of Robert A. Kyle Award

Friday, October 28, 2022

[7:30-9:00] Session VI

Prognostic and Predictive Markers

Prashant Kapoor, Efstathios Kastritis, [Chairs]

 

Models-Risk Stratification of Asymptomatic WM

Romanos Sklavenitis-Pistofidis, Dana Farber Cancer Institute, USA

 

Predictors of Short Survival in WM

Prashant Kapoor, Mayo Clinic, USA

 

Impact of 6q on WM clinical outcomes

Ramon Garcia-Sanz, University of Salamanca, Spain

 

Clinical Response Predictors for BTK-I

Jithma Abeykoon, Mayo Clinic, USA

 

CXCR4 subtype and clonality impact ibrutinib response

Joshua Gustine, Dana Farber Cancer Institute, USA

 

Prognostic Impact of MYD88 L265P by ddPCR

Carlos Fernandez de Larrea, Hospital Clinic Barcelona, Spain

 

[9:00-9:30] Morning Break

  

[9:30-11:15] Session VII

Chemoimmunotherapy

Veronique Leblond, Luigi Qiu [Chairs]       

 

B-RCD vs. RCD Randomized Trial in WM

Pierre Morel, Centre Hospitalier Universitaire Amiens Picardie, France

 

RCD vs BCD Randomized Trial

Lugui Qiu, National Clinical Research Center for Blood Diseases, China

 

Bendamustine/Rituximab: Dose Intensity and Patient Outcomes

Suzanne Arulogun, UC London Hospitals NHS, UK

 

FILO Bendamustine Rituximab

Veronique Leblond, Hôpital Pitié Salpêtrière, France

 

HOVON 124: Ixazomib, Dex., Rituximab in Previously Treated WM

M.J. Kersten, University of Amsterdam, Netherlands

 

STIL Maintenance Rituximab

Mathias Rummel, University of Giessen, Germany

 

BRB: Bendamustine, Rituximab, Bortezomib Study: Fondazione Italiana Linfomi Study

Giulia Benevolo, University of Torino, Italy

 

[11:15-11:45] Keynote Lectures

 

Benda or BTK-I for frontline WM treatment: Insights from CLL SEQUOIA Trial

Keynote Speaker: Constantine Tam, Peter MacCallum Cancer Centre, Australia

 

Mechanistic Insights into Adverse Events underlying BTK-inhibitors

Keynote Speaker: C.I. Edvard Smith, Karolinska Institut, Sweden

 

[11:45-12:45] LUNCH

 

[12:45-14:30] Session VIII

BTK-Inhibitors I

Judith Trotman, Meletios Dimopoulos [Chairs]

 

Long Term Follow-Up of Ibrutinib Monotherapy in Previously Treated WM

Steven Treon, Dana Farber Cancer Institute, USA

 

INNOVATE C/Update

Meletios Dimopoulos, University of Athens, Greece

 

Long Term Follow-Up of Ibrutinib Monotherapy in Frontline WM

Jorge Castillo, Dana Farber Cancer Institute, USA

 

Long Term Follow-up-INNOVATE A/B

Christian Buske, University Hospital Ulm, Germany

 

Real World Experiences with Ibrutinib-US experience

Jithma Abeykoon, Mayo Clinic, USA

 

Real World Experiences with Ibrutinib-UK experience

Shirley D’Sa, UC London Hospitals NHS, UK

 

Real World Data on CIT and BTK-inhibitors: WHIMSICAL Study

Ibrahim Tohidi-Esfahani, University of Sydney, Australia

 

 

 

[14:30-15:45] Session IX

BTK-Inhibitors II

Alessandra Tedeschi, Constantine Tam, [Chairs]

 

Long Term Follow-up-Acalabrutinib Phase II

Roger Owen, Leeds Hospital NHS Trust, UK

 

Long Term Follow-Up Zanubrutinib-Phase II

Judith Trotman, University of Sydney, Australia

 

Phase II Zanubrutinib in relapsed/refractory WM: Chinese experience

Lugui Qui, National Clinical Research Center for Blood Diseases, China

 

Long Term Follow-up-ASPEN

Constantine Tam, Peter MacCallum Cancer Centre, Australia

 

Long Term Follow-Up of Zanubrutinib in MYD88 WT WM

Meletios Dimopoulos, University of Athens, Greece

 

[15:45-16:15] Afternoon Break

 

[16:15-17:30] Session: X

Management of BTK-inhibitor exposed patients

Shayna Sarosiek, Carlos De Larrea [Chairs]

 

Dose reduction of ibrutinib and impact on treatment course

Shayna Sarosiek, Dana Farber Cancer Institute, USA

 

Zanubrutinib in patient’s intolerant to ibrutinib/acalabrutinib

Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA

 

Venetoclax in Previously Treated WM incl. BTK-inhibitor exposed patients

Jorge Castillo, Dana Farber Cancer Institute, USA

 

Pirotbrutinib in Previously Treated WM Patients with Covalent BTK-inhibitor

  1. L. Palomba, Memorial Sloan Kettering Cancer Center, USA

 

MK-1026 Dose Expansion Study in B-cell malignancies incl WM

Deborah Stephens, University of Utah, Huntsman Cancer Institute, USA

 

[17:30] Day Adjournment

 

[18:30] Faculty Dinner Reception

Saturday, October 29, 2022

[7:30-10:15] Session XI

Great Debates in WM

Eva Kimby, Jesus San Miguel [Chairs]

 

[7:30-8:00] Great Debate I

Should we treat smoldering WM? -No

Prashant Kapoor, Mayo Clinic, USA

 

Should we treat smoldering WM? -Yes

Irene Ghobrial, Dana Farber Cancer Institute

 

[8:00-8:30] Great Debate II

Should BTK-I or Benda-R be the standard frontline induction regimen? -for Benda-R

Christian Buske, University Hospital Ulm, Germany

 

Should BTK-I or Benda-R be the standard frontline induction regimen? -for BTK-I

Meletios Dimopoulos, University of Athens, Greece

 

[8:30-9:15] Great Debate III

Does the choice of BTK-inhibitor matter? -for Ibrutinib

Ranjana Advani, Stanford University Medical Center, USA

 

Does the choice of BTK-inhibitor matter? -for Acalabrutinib

Roger Owen, Leeds Hospital NHS Trust, UK

 

Does the choice of BTK-inhibitor matter? -for Zanubrutinib

Judith Trotman, University of Sydney, Australia

 

[9:15-9:45] Great Debate IV

Managing the ibrutinib intolerant patient: Dose reduce or switch to another BTK-inhibitor? -Dose reduce

M Lia Palomba, Memorial Sloan Kettering Cancer Center, USA

 

Managing the ibrutinib intolerant patient: Dose reduce or switch to another BTK-inhibitor? -Switch

Alexandra Tedeschi, Niguarda Hopital, Italy

 

 

 

 

[9:45-10:15] Great Debate V

What should be the end point of therapy in WM? -Disease control should be the endpoint of therapy

Stathis Kastritis, University of Athens, Greece

 

What should be the end point of therapy in WM? -CR should be the endpoint of therapy

Jorge Castillo, Dana Farber Cancer Institute, USA

 

[10:15-10:45] Morning Break

 

[10:45-11:45] Session XII

Novel Treatment Approaches to WM-Clinical I

Sheeba Thomas, Moshe Gatt [Chairs]

 

Venetoclax in combination with ibrutinib for WM

Jorge Castillo, Dana Farber Cancer Institute, USA

 

Targeting mutated CXCR4 in WM

Steven Treon, Dana Farber Cancer Institute, USA

 

Obinutuzumab and Idelalisib in WM

Veronique Leblond, Hôpital Pitié Salpêtrière, France

 

Acalabrutinib and Rituximab for WM and IGM RD PN

Shayna Sarosiek, Dana Farber Cancer Institute, USA

 

[11:45-12:30] Session XIII

Novel Treatment Approaches to WM-Clinical II

Jorge Castillo, Stephen Ansell [Chairs]

 

Tirabrutinib in Treatment Naïve and Prev Treated WM-Phase II

Koji Izutsu, National Cancer Center Hospital, Japan

 

Phase II study of Orelabrutinib in relapsed/refractory WM

Xinxin Cao, Peking Union Medical College, China

 

Clinical Activity of IRAK4 Inhibitor CA-4948 in NHL, incl. WM

Reinhard Von Roemeling, Curis Pharmaceuticals, USA

 

 

[12:30-13:30] LUNCH

 

[13:30-14:30] Session XIV

Novel Treatment Approaches to WM-Clinical III

Merav Leiba, Shirley D’Sa [Chairs]

 

Bispecifics in WM-CD3XCD20 RGN1979

Stephen Ansell, Mayo Clinic, USA

 

Phase II Study of Loncastuximab in WM

Shayna Sarosiek, Dana Farber Cancer Institute, USA

 

Idiotype DNA Vaccine Therapy for WM

Sheeba Thomas, MD Anderson, USA

 

CD20 CAR-T therapy for WM and other B-NHLs

Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA

 

[14:30-15:00] Keynote Lectures

 

Bi-specifics and Conjugated Antibodies: MM Experience

Keynote Speaker: Kenneth C. Anderson, Dana Farber Cancer Institute, USA

 

Bringing CART to WM: Which One?

Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA

 

[15:00-15:30] Afternoon Break

 

[15:30-16:30] Session XVI

Plenary

Veronique Leblond, Jésus San Miguel [Chairs]

 

Presentation 1

TBD

 

Presentation 2

TBD

 

Presentation 3

TBD

 

Presentation 4

TBD

 

 

[16:30-17:15] Session XVII

Special Topics Lectures

 

Clinical Characteristics and Outcomes with Cryoglobulinemia in WM

Speaker: Shirley D’Sa, UC London Hospitals NHS, UK

 

Clinical Characteristics and Outcomes with Cold Agglutinins in WM

Speaker: Josephine Vos, University of Amsterdam, Netherlands

 

Management of Amyloidosis in WM Patients

Speaker: Giampaolo Merlini, University of Pavia, Italy

 

[17:15] Day Adjournment

 

[19:30] Dinner Reception & Closing Ceremonies

Presentation of Peter S. Bing Humanitarian Awards

Presentation of Jan Gosta Waldenstrom Awards

Sunday, October 30, 2022

[9:00] Keynote Lectures

 

Challenges of COVID in WM Patient Care

Keynote Speaker: Meletios Dimopoulos, University of Athens, Greece

 

[9:15-10:30] Session XV

COVID and WM

Ramon Garcia Sanz, Andrew Branagan [Chairs]

 

Responses to COVID vaccination in WM and MM Patients

Andrew Branagan, Massachusetts General Hospital, USA

 

Responses to COVID vaccination (initial and booster dose) in patients with plasma cell neoplasms

Evangelos Terpos, University of Athens, Greece

 

GETH-TC Study on Serological responses to initial vaccination and booster in heme patients

with /without prior COVID19

Ramon Garcia-Sanz, University of Salamanca, Spain

 

Efficacy of BNT162b2 in WM and FLL -Australian Experience

Judith Trotman, University of Sydney, Australia

 

Impact of Booster Vaccination on SARS-COV-2 Antibody Levels in Blood CA Patients incl. WM

Lee Greenberger, Leukemia Lymphoma Society (LLS), USA

 

[10:30] Day Adjournment

 

[10:30-11:00] Morning Break

 

[11:00-1:00] Panel Discussions

WM Management I

 

WM Consensus Panel I Report

IWWM-11 Recommendation for Treatment Approach in WM-Frontline

Organizers: Christian Buske, Jorge Castillo, Judith Trotman

 

 

WM Consensus Panel II Report

IWWM-11 Recommendation for Treatment Approach in WM-Relapsed/Refractory

Organizers: Efstathios Kastritis, Shirley D'SA, Jeffrey Matous

 

WM Consensus Panel III Report

IWWM-11 Recommendation for Molecular Diagnostic Workup in WM

Organizers: Ramon Garcia-Sanz, Marzia Varettoni, Zachary Hunter

 

WM Consensus Panel IV Report

Response Criteria for WM

Organizers: Steve Treon, Roger Owen, Alessandra Tedeschi

 

[13:00-14:00] LUNCH

 

[14:00-15:30] Panel Discussions

WM Management II

 

WM Consensus Panel V Report

COVID Prophylaxis and Management in WM

Organizers: Meletios Dimopoulos, Veronique LeBlond, Andrew Branagan

 

WM Consensus Panel VI Report

Management of WM-related Amyloidosis

Organizers: Monique Minnema, Shayna Sarosiek, Giampaolo Merlini

 

WM Consensus Panel VII Report

Priorities for Novel Clinical Trials

Organizers: MJ Kersten, Prashant Kapoor, Constantine Tam

 

The Bing Center

ing Center for Waldenstrom's Macroglobulinemia
Dana Farber Cancer Institute
Harvard Medical School

Contact

Christopher Patterson
Secretariat

Address

450 Brookline Avenue

Mayer 548

Boston, MA 02215

p +1 617 632 6285

f +1 617 632 4862

Newsletter

Enter your email address for news about the 11th IWWM.